Copy
See below for a Thursday morning overview of recent MS news
View this email in your browser
Updates from

Multiple Sclerosis News Today

The Web's Daily Resource for Multiple Sclerosis News

In the 07/30/2015 edition:

Share
Tweet
Share
+1
Forward
Excerpts:

Altered Immune Cells in Relapsing Remitting Multiple Sclerosis Patients Cause Reduced Immune Capacity

In a new study entitled “Polymorphonuclear Cell Functional Impairment in Relapsing Remitting Multiple Sclerosis Patients: Preliminary Data” researchers investigated how polymorphonuclear cells — important players of the innate immune system — are altered in multiple sclerosis patients. The study was published in the journal PLOS One. Multiple Sclerosis (MS) is an autoimmune disease that affects the central […]

The post Altered Immune Cells in Relapsing Remitting Multiple Sclerosis Patients Cause Reduced Immune Capacity appeared first on Multiple Sclerosis News Today.


Read on »

Ashkenazi Jews' Relative Multiple Sclerosis Susceptibility Subject Of New Study

An Open Access research article published in the journal BMC Medical Genetics notes that multiple sclerosis (MS) has a strong genetic component, observing high MS prevalence in European populations including those of Ashkenazi Jewish origin, and low in African and Asian populations also including those of Jewish origin. MS is an autoimmune disease of the […]

The post Ashkenazi Jews' Relative Multiple Sclerosis Susceptibility Subject Of New Study appeared first on Multiple Sclerosis News Today.


Read on »

MS Study Uses Findings on Quality of Life Issues To Develop New Confidence-Building Intervention

The major challenge patients with multiple sclerosis face is nearly constant muscle weakness and fatigue caused by progressive nerve and neurological damage. It is well established that these symptoms dramatically affect quality of life in MS patients, making it more difficult to work, partake in hobbies, and enjoy family and social interactions. According to Matthew Plow, an […]

The post MS Study Uses Findings on Quality of Life Issues To Develop New Confidence-Building Intervention appeared first on Multiple Sclerosis News Today.


Read on »

Biogen’s Tecfidera Now The Most Prescribed Oral MS Therapy Globally

Cambridge, Massachusetts based Biogen Inc. has reported its second quarter 2015 results, posting a year-over-year seven percent revenue increase to $2.6 Billion in the quarter. “Biogen remains focused on improving the lives of people living with complex diseases,” says Chief Executive Officer George A. Scangos, Ph.D. “Tecfidera, which is now the most prescribed oral MS […]

The post Biogen’s Tecfidera Now The Most Prescribed Oral MS Therapy Globally appeared first on Multiple Sclerosis News Today.


Read on »

Masitinib Shows Promise in Study For Treating Progressive MS Patients

Progressive multiple sclerosis patients treated with AB Science’s lead compound AB07002 (masitinib) in a Phase 3 clinical trial showed positive results in a non futility test (a test to determine if an experimental therapy shows some sign of efficacy). With the successful completion of the futility analysis, AB Science is justified to continue the remainder […]

The post Masitinib Shows Promise in Study For Treating Progressive MS Patients appeared first on Multiple Sclerosis News Today.


Read on »

Copyright © 2015 BioNews Services, LLC, All rights reserved.


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp